Skip to main content
Addgene

pWPI-IRES-Puro-Ak-ACE2-TMPRSS2 Citations (7)

Originally described in: Best Lab Plasmids
Unpublished

Articles Citing pWPI-IRES-Puro-Ak-ACE2-TMPRSS2

Articles
SARS CoV-2 Nucleoprotein Enhances the Infectivity of Lentiviral Spike Particles. Mishra T, Sreepadmanabh M, Ramdas P, Sahu AK, Kumar A, Chande A. Front Cell Infect Microbiol. 2021 Apr 23;11:663688. doi: 10.3389/fcimb.2021.663688. eCollection 2021. PubMed

Associated Plasmids

Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL. Viruses. 2021 Jun 26;13(7). pii: v13071246. doi: 10.3390/v13071246. PubMed
NSP4 and ORF9b of SARS-CoV-2 Induce Pro-Inflammatory Mitochondrial DNA Release in Inner Membrane-Derived Vesicles. Faizan MI, Chaudhuri R, Sagar S, Albogami S, Chaudhary N, Azmi I, Akhtar A, Ali SM, Kumar R, Iqbal J, Joshi MC, Kharya G, Seth P, Roy SS, Ahmad T. Cells. 2022 Sep 23;11(19):2969. doi: 10.3390/cells11192969. PubMed
Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. Azuma H, Kawano Y, Shitaoka K, Kawahara T, Ito A, Higashiura A, Kitajima Y, Ohki S, Yasuda T. Int Immunol. 2023 Apr 4;35(4):197-207. doi: 10.1093/intimm/dxac055. PubMed
Virus-like particle - mediated delivery of the RIG-I agonist M8 induces a type I interferon response and protects cells against viral infection. Palermo E, Alexandridi M, Di Carlo D, Muscolini M, Hiscott J. Front Cell Infect Microbiol. 2022 Dec 14;12:1079926. doi: 10.3389/fcimb.2022.1079926. eCollection 2022. PubMed
Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. Kroll MK, Schloer S, Candan P, Korthals N, Wenzel C, Ihle H, Gilhaus K, Liedtke KR, Schofbanker M, Surmann B, Schroter R, Neugebauer U, Mall G, Oswald S, Ludwig S, Rescher U, Vollenbroker B, Ciarimboli G. Biomolecules. 2023 Mar 3;13(3):472. doi: 10.3390/biom13030472. PubMed
Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Shitaoka K, Higashiura A, Kawano Y, Yamamoto A, Mizoguchi Y, Hashiguchi T, Nishimichi N, Huang S, Ito A, Ohki S, Kanda M, Taniguchi T, Yoshizato R, Azuma H, Kitajima Y, Yokosaki Y, Okada S, Sakaguchi T, Yasuda T. Commun Biol. 2023 Apr 11;6(1):395. doi: 10.1038/s42003-023-04782-6. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.